

**Amendments to the Claims:**

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

What is claimed is:

1. ~~(Canceled) A method of improving skin quality comprising topically applying to the skin an IRM compound selected from the group consisting of an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2 bridged imidazoquinoline amine, a 6,7 fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphthyridine amine, a thiazolonaphthyridine amine, or a combination thereof, in an amount effective to improve the quality of the skin by reversing changes in the dermis selected from the group consisting of diminution in the number and diameter of elastic fibers in the papillary dermis, atrophy of the dermis, reduction in subcutaneous adipose tissue, deposition of abnormal elastic materials in the upper dermis, or a combination thereof.~~
2. ~~(Canceled) The method of claim 1 wherein the IRM compound is an agonist of at least one TLR.~~
3. ~~(Canceled) The method of claim 2 wherein the IRM compound is an agonist of TLR7, TLR8, or both TLR7 and TLR8.~~
4. ~~(Canceled) The method of claim 1 wherein the IRM compound is administered via a topical application vehicle.~~

5. ~~(Canceled) The method of claim 4 wherein the topical application vehicle comprises a cream, a foam, a gel, a spray, an ointment, a lotion, a solution, a suspension, a dispersion, an emulsion, a microemulsion, a paste, a powder, a wipe, or an oil.~~

6. ~~(Cancelled).~~

7. ~~(Canceled) A method of visibly reducing a skin change associated with aging comprising:~~

~~topically applying to skin exhibiting a change associated with aging an IRM compound in an amount and for a period of time sufficient to visibly reduce the skin change associated with aging by reversing changes in the dermis selected from the group consisting of diminution in the number and diameter of elastic fibers in the papillary dermis, atrophy of the dermis, reduction in subcutaneous adipose tissue, deposition of abnormal elastic materials in the upper dermis, or a combination thereof; wherein the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, or a combination thereof.~~

8. (Currently amended) A method of visibly reducing a human skin wrinkle comprising:

topically applying to the human skin wrinkle an IRM compound that is an agonist of TLR7, TLR8, or both TLR7 and TLR8 in an amount and for a period of time sufficient to visibly reduce the wrinkle; wherein the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, a thiazolonaphthyridine amine, or a combination thereof.

9. ~~(Canceled) A method of treating aging related skin conditions comprising:~~

~~topically applying to the skin an IRM compound for a period of time and in an amount sufficient to effect changes in the dermis by reversing changes in the dermis selected from the group consisting of diminution in the number and diameter of elastic fibers in the papillary dermis, atrophy of the dermis, reduction in subcutaneous adipose tissue, deposition of abnormal elastic materials in the upper dermis, or a combination thereof, wherein the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphththyridine amine, a tetrahydroimidazonaphththyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphththyridine amine, a thiazolonaphththyridine amine, or a combination thereof.~~

10. ~~(Canceled) A method for reducing the appearance of skin changes associated with aging comprising:~~

~~topically applying to an area of skin exhibiting skin changes associated with aging an IRM compound in an amount and for a period of time sufficient to reduce the appearance of said skin changes associated with aging by reversing changes in the dermis selected from the group consisting of diminution in the number and diameter of elastic fibers in the papillary dermis, atrophy of the dermis, reduction in subcutaneous adipose tissue, deposition of abnormal elastic materials in the upper dermis, or a combination thereof, wherein the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphththyridine amine, a tetrahydroimidazonaphththyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphththyridine amine, a thiazolonaphththyridine amine, or a combination thereof.~~

11. (Canceled) A method for improving the quality of facial skin comprising: ~~topically applying to facial skin an IRM compound in an amount and for a period of time sufficient to reverse changes in the dermis selected from the group consisting of diminution in the number and diameter of elastic fibers in the papillary dermis, atrophy of the dermis, reduction in subcutaneous adipose tissue, deposition of abnormal elastic materials in the upper dermis, or a combination thereof, and wherein the IRM compound is an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazonaphthyridine amine, a thiazolonaphthyridine amine, or a combination thereof.~~